CRISPR/Cas9 knockout and AI-based drug screening for novel gene targets in ovarian cancer chemoresistance (AACR 2025) - Mar 26, 2025 - Abstract #4408; Pres time: Apr 29, 2025; 09:00 AM - 12:00 PM; Location: Section 22; Poster Board No: 11; "Introduction: Ovarian cancer, characterized by its heterogeneity and resistance to conventional therapies such as cisplatin (CDDP), presents a significant clinical challenge...This integrated approach aims to reveal genetic determinants and actionable therapeutic targets to improve treatment outcomes. We performed genome-scale CRISPR/Cas9 knockout screening in ovarian cancer cell lines treated with CDDP, erastin, and a combination of elesclomol and copper (ES+Cu), identifying genes involved in drug resistance mechanisms... This study integrates CRISPR-based screening, scRNA-seq, and virtual screening to provide the first comprehensive framework for addressing drug resistance in ovarian cancer. The identification of YTHDC2 as a key resistance-related gene and the validation of Proguanil, Calcipotriol, and Sildenafil as potential therapeutics underscore the translational potential. These findings offer new avenues for precision oncology, with the goal of improving..."
Oncology • Ovarian Cancer • Solid Tumor • YTHDC2 • ZFAS1
|
|
Jinjiang Wang; Jiaxi Li; Jiao Liu; Kit-Ying Chan; Ho-Sze Lee; Zhewei Zhang; Joseph Kwong; Tat-San Lau; Chi-Chiu Wang
|